Catalyst Pharmaceuticals, Inc. Common Stock Earnings Dividend

Catalyst Pharmaceuticals, Inc. Common Stock’s revenue jumped 5.63% since last year same period to $149.39Mn in the Q1 2026. On a quarterly growth basis, Catalyst Pharmaceuticals, Inc. Common Stock has generated -2.11% fall in its revenue since last 3-months.

Catalyst Pharmaceuticals, Inc. Common Stock’s net profit jumped 12.33% since last year same period to $63.73Mn in the Q1 2026. On a quarterly growth basis, Catalyst Pharmaceuticals, Inc. Common Stock has generated 20.94% jump in its net profits since last 3-months.

Catalyst Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 6.34% since last year same period to 42.66% in the Q1 2026. On a quarterly growth basis, Catalyst Pharmaceuticals, Inc. Common Stock has generated 23.55% jump in its net profit margins since last 3-months.

Catalyst Pharmaceuticals, Inc. Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 18.14.

Catalyst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.64 - a 115.7% jump from last quarter’s estimates.

Catalyst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.64.

Catalyst Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) jumped 75.56% since last year same period to 0.79 in the Q1 2026. This indicates that the Catalyst Pharmaceuticals, Inc. Common Stock has generated 75.56% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Catalyst Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at 0.16.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Catalyst Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at 0.25.